March 16 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:
BIOMARIN PHARMACEUTICAL INC - DISCONTINUES PHASE 2 VOXZOGO TRIALS IN TURNER SYNDROME, SHOX-DEFICIENCY, ACAN-DEFICIENCY - SEC FILING
BIOMARIN: DECISION TO DISCONTINUE FOLLOWING OCCURRENCE OF SEVERAL SLIPPED CAPITAL FEMORAL EPIPHYSIS EVENTS IN 2 ONGOING INVESTIGATOR-SPONSORED TRIALS
BIOMARIN PHARMACEUTICAL - PHASE 2 CANOPY TRIALS OF VOXZOGO IN NOONAN SYNDROME, IDIOPATHIC SHORT STATURE TO CONTINUE - SEC FILING
Source text: []